camptothecin has been researched along with pyrroles in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.08) | 18.7374 |
| 1990's | 3 (6.12) | 18.2507 |
| 2000's | 10 (20.41) | 29.6817 |
| 2010's | 34 (69.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beerman, TA; McHugh, MM; Sigmund, RD | 1 |
| Kann, HE; Kohn, KW | 1 |
| Horwitz, SB | 1 |
| Li, CJ; Pardee, AB; Wang, C | 1 |
| Czarnik, AW; Galan, AA; Halim, NS; Heldsinger, A; Loo, JA; Mack, DP; Mei, HY; Moreland, DW; Sannes-Lowery, KA; Sharmeen, L; Truong, HN | 1 |
| Berlin, JD | 1 |
| Cagir, A; Eisenhauer, BM; Gao, R; Hecht, SM; Jones, SH | 1 |
| Broggini, M; Colombo, T; Geroni, C; Marchini, S; Sabatino, MA | 1 |
| Cheng, K; Eisenhauer, BM; Gao, R; Hecht, SM; Rahier, NJ; Thomas, SJ | 1 |
| Abbruzzese, JL; Bogaard, K; Hoff, PM; Waldrum, S; Wolff, RA | 1 |
| Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD | 1 |
| Borner, MM | 1 |
| Liu, GS; Yao, ZJ; Zhou, HB | 1 |
| Allegrini, G; Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Fanelli, G; Fioravanti, A; Kerbel, RS; Naccarato, AG; Orlandi, P; Viacava, P | 1 |
| Bar-Eli, M; Fan, D; Fidler, IJ; Kerbel, RS; Kim, SJ; Kuwai, T; Nakamura, T; Sasaki, T; Villares, GJ; Wang, H; Zigler, M | 1 |
| Dianov, GL; Fanta, M; Freschauf, GK; Grassot, JM; Hall, DG; Mani, RS; Mereniuk, TR; Virgen, CA; Weinfeld, M | 1 |
| Corda, E; Girotti, S; González-Ruiz, V; Martín, MA; Mussardo, P; Olives, AI | 1 |
| Bjerregaard, JK; Jensen, BV; Jorgensen, TL; Nielsen, D; Pfeiffer, P; Qvortrup, C | 1 |
| Belcastro, V; Bosotti, R; Brunetti-Pierri, N; di Bernardo, D; Ferriero, R; Iorio, F; Isacchi, A; Mithbaokar, P; Murino, L; Scacheri, E; Tagliaferri, R | 1 |
| Armand, JP; Boven, E; Brega, NM; Countouriotis, AM; Hartog, V; Massard, C; Ruiz-Garcia, A; Soria, JC; Tillier, C | 1 |
| Aohara, F; Fujimura, Y; Harakawa, N; Hasegawa, R; Katori, N; Kim, SR; Maekawa, K; Naito, M; Niwa, T; Okuda, H; Sai, K; Saito, Y; Sawada, J; Tohkin, M; Yoshimura, T | 1 |
| Arends, J; Büchert, M; Fasol, U; Fischer, R; Hense, J; Jaehde, U; Kanefendt, F; Moritz, B; Mross, K; Scheulen, ME; Strumberg, D | 1 |
| Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Bucci, F; Cassinelli, G; Cominetti, D; De Cesare, M; Di Francesco, AM; Lanzi, C; Meco, D; Orlandi, A; Passeri, D; Petrangolini, G; Pisano, C; Riccardi, R; Tortoreto, M; Zaffaroni, N; Zuco, V; Zunino, F | 1 |
| Denda, T; Hashigaki, S; Kato, T; Komatsu, Y; Lechuga, MJ; Miyata, Y; Mizutani, N; Muro, K; Nagase, M; Nishina, T; Satoh, T; Tsuji, A; Tsuji, Y; Yoshida, M | 1 |
| Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS | 1 |
| Higashiyama, K; Iwase, Y; Maitani, Y; Saito, H; Seishi, Y; Sugino, T; Yamauchi, T | 1 |
| Jahng, Y; Jeong, TC; Kim, DH; Lee, J; Lee, S | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Boers-Sonderen, MJ; Desar, IM; Koopman, M; Punt, CJ; van Herpen, CM | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D | 1 |
| Bianchini, G; Fernández-Marcelo, T; González-Ruiz, V; Iniesta, P; Martín, MA; Menéndez, JC; Olives, AI; Pascua, I; Ramos, MT; Ribelles, P; Sridharan, V | 1 |
| Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
| Amendola, V; Litti, L; Meneghetti, M; Toffoli, G | 1 |
| Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H | 1 |
| Deininger, E; Moch, H; Razafinjatovo, CF; Rechsteiner, M; Schraml, P; Stiehl, D | 1 |
| Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T | 1 |
| Alì, G; Antonelli, A; Basolo, F; Bocci, G; Di Desidero, T; Ferrari, SM; Fioravanti, A; Fontanini, G; Francia, G; Orlandi, P | 1 |
| Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I | 1 |
| Al-Batran, SE; Galle, PR; Gehrke, N; Goepfert, K; Grimminger, P; Hegewisch-Becker, S; Maderer, A; Möhler, M; Nagel, M; Schattenberg, JM; Schulz, J; Thomaidis, T; Thuss-Patience, PC | 1 |
| Ayyanaar, S; Kesavan, MP; Kotla, NG; Kumar, GGV; Rajagopal, G; Rajesh, J; Sivaraman, G; Webster, TJ | 1 |
| Hu, X; Qin, H; Xing, D; Yan, H; Yang, J; Zhai, S | 1 |
| Argiriadi, MA; Baranczak, A; Friedman, MM; Gavrilyuk, J; Hobson, AD; Hulce, JJ; Osman, S; Vasudevan, A; Wilson, NS | 1 |
| Du, Y; Fang, J; Guo, X; Jin, Y; Liang, X; Lu, W; Sun, W; Tian, J; Yu, C; Zheng, J | 1 |
| Almansour, AI; Altaf, M; Arumugam, N; Bianchini, G; Dupadahalli, K; Kumar, RS; Menéndez, JC; Mohammad, F | 1 |
4 review(s) available for camptothecin and pyrroles
| Article | Year |
|---|---|
Novel inhibitors of RNA synthesis.
Topics: Acrylamides; Animals; Antibiotics, Antineoplastic; Benzoates; Benzodiazepinones; Bleomycin; Camptothecin; Centrifugation, Density Gradient; Cycloparaffins; Depression, Chemical; DNA; DNA Replication; DNA-Directed RNA Polymerases; Escherichia coli; HeLa Cells; Lactones; Leukemia L1210; Mitosis; Nucleic Acid Denaturation; Pyrroles; RNA; RNA, Ribosomal; RNA, Viral; Structure-Activity Relationship; Templates, Genetic; Uracil Nucleotides; Uridine; Vaccinia virus; Virus Replication; Xanthenes | 1974 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fluorouracil; Humans; Indoles; Irinotecan; Leucovorin; Male; Neovascularization, Pathologic; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2002 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
14 trial(s) available for camptothecin and pyrroles
| Article | Year |
|---|---|
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Treatment Outcome | 2006 |
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib | 2011 |
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Young Adult | 2011 |
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2012 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Irinotecan; Maximum Tolerated Dose; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome | 2013 |
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pyrroles; Stomach Neoplasms; Sunitinib | 2016 |
Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Keratin-18; Leucovorin; Male; Middle Aged; Peptide Fragments; Placebos; Pyrroles; Stomach Neoplasms; Sunitinib | 2018 |
31 other study(ies) available for camptothecin and pyrroles
| Article | Year |
|---|---|
Effects of minor groove binding drugs on camptothecin-induced DNA lesions in L1210 nuclei.
Topics: Animals; Benzimidazoles; Bisbenzimidazole; Camptothecin; Cell Nucleus; Distamycins; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Interactions; Indoles; Leukemia L1210; Molecular Structure; Pyrroles; Topoisomerase I Inhibitors | 1990 |
Effects of deoxyribonucleic acid-reactive drugs on ribonucleic acid synthesis in leukemia L1210 cells.
Topics: Acridines; Acrylamides; Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzazepines; Camptothecin; Carbazoles; Carbon Isotopes; Cell Nucleolus; Cell Nucleus; Centrifugation, Density Gradient; Dactinomycin; Daunorubicin; Deoxyadenosines; DNA, Neoplasm; Ethidium; Leukemia L1210; Mechlorethamine; Methionine; Phenanthridines; Pyridines; Pyrroles; RNA, Neoplasm; Tritium; Uridine | 1972 |
Camptothecin inhibits Tat-mediated transactivation of type 1 human immunodeficiency virus.
Topics: Base Sequence; Benzodiazepines; Camptothecin; Cell Line; Gene Expression Regulation, Viral; Gene Products, tat; HIV Long Terminal Repeat; HIV-1; Humans; Molecular Sequence Data; NF-kappa B; Oligodeoxyribonucleotides; Pyrroles; Regulatory Sequences, Nucleic Acid; tat Gene Products, Human Immunodeficiency Virus; Transcriptional Activation | 1994 |
Discovery of selective, small-molecule inhibitors of RNA complexes--I. The Tat protein/TAR RNA complexes required for HIV-1 transcription.
Topics: Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Base Sequence; Benzodiazepinones; Camptothecin; Gene Products, tat; HeLa Cells; HIV-1; Humans; Molecular Sequence Data; Pyrroles; RNA, Viral; tat Gene Products, Human Immunodeficiency Virus; Transcription, Genetic; Transcriptional Activation; Virus Replication | 1997 |
Luotonin A. A naturally occurring human DNA topoisomerase I poison.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Pyrroles; Quinones; Topoisomerase I Inhibitors | 2003 |
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colonic Neoplasms; DNA; Doxorubicin; Female; Glutathione; Glutathione Transferase; Guanidines; Irinotecan; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred DBA; Mice, Nude; Pyrroles; Transplantation, Heterologous | 2003 |
14-azacamptothecin: a potent water-soluble topoisomerase I poison.
Topics: Camptothecin; Enzyme Inhibitors; Humans; Kinetics; Pyrroles; Quinones; Solubility; Topoisomerase I Inhibitors; Water | 2005 |
Short and efficient total synthesis of luotonin A and 22-hydroxyacuminatine using a common cascade strategy.
Topics: Camptothecin; Chemistry, Organic; Fluorenes; Indolizines; Models, Chemical; Molecular Conformation; Pyrroles; Quinolines; Quinones | 2007 |
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Immunoenzyme Techniques; Immunohistochemistry; Indoles; Irinotecan; Male; Mice; Mice, Nude; Microcirculation; Pyrroles; Thrombospondin 1; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2008 |
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Cecum; Cell Proliferation; Colonic Neoplasms; Drug Therapy, Combination; Endothelial Cells; Enzyme Inhibitors; ErbB Receptors; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Irinotecan; Lymphatic Metastasis; Male; Mice; Mice, Nude; Necrosis; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; RNA, Small Interfering; Topoisomerase I Inhibitors; Transforming Growth Factor alpha | 2008 |
Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Binding Sites; Camptothecin; Cell Survival; Circular Dichroism; DNA Ligase ATP; DNA Ligases; DNA Polymerase beta; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fluorescence Resonance Energy Transfer; Humans; Lung Neoplasms; Mutagenesis, Site-Directed; Phosphotransferases (Alcohol Group Acceptor); Photoelectron Spectroscopy; Piperidines; Poly-ADP-Ribose Binding Proteins; Protein Conformation; Pyrroles; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenopus Proteins | 2010 |
Liquid chromatographic analysis of the anticancer alkaloid luotonin A and some new derivatives in human serum samples.
Topics: Alkaloids; Animals; Antineoplastic Agents; Camptothecin; Chromatography, Liquid; Humans; Molecular Structure; Pyrroles; Quinones; Reproducibility of Results | 2010 |
Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Compassionate Use Trials; Denmark; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Sunitinib; Treatment Outcome | 2010 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blotting, Western; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Discovery; Drug Screening Assays, Antitumor; Flavonoids; Fuzzy Logic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Irinotecan; Neoplasms; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperidines; Pyrazoles; Pyrroles; RNA Polymerase II | 2010 |
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.
Topics: Alleles; Animals; Asia, Eastern; Atorvastatin; Biocatalysis; Camptothecin; Carbamazepine; Cytochrome P-450 CYP3A; Docetaxel; Heptanoic Acids; Humans; Irinotecan; Midazolam; Models, Molecular; Paclitaxel; Pyrroles; Spodoptera; Substrate Specificity; Taxoids; Terfenadine | 2010 |
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; DNA Topoisomerases, Type I; Female; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Mice, Nude; Pyrroles; Receptors, Scavenger; Rhabdomyosarcoma; Sarcoma; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Immunohistochemistry; Indoles; Irinotecan; Liposomes; Mice; Mice, Nude; PC12 Cells; Pyrroles; Rats; Sunitinib; Tissue Distribution | 2012 |
Characterization of in vitro metabolites of luotonin A in human liver microsomes using electrospray/tandem mass spectrometry.
Topics: Biotransformation; Camptothecin; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Enzyme Inhibitors; Humans; Hydroxylation; Isoenzymes; Metabolic Networks and Pathways; Microsomes, Liver; Molecular Weight; Protons; Pyrroles; Quinones; Recombinant Proteins; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
B-ring-aryl substituted luotonin A analogues with a new binding mode to the topoisomerase 1-DNA complex show enhanced cytotoxic activity.
Topics: Amino Acids; Antineoplastic Agents; Camptothecin; Cerium; Chemistry, Pharmaceutical; Crystallization; DNA; DNA Topoisomerases, Type I; HeLa Cells; Humans; Hydrogen Bonding; Ligands; Magnetic Resonance Spectroscopy; Molecular Conformation; Nitrates; Protein Binding; Pyrroles; Quinones; Topoisomerase I Inhibitors | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Detection of low-quantity anticancer drugs by surface-enhanced Raman scattering.
Topics: Antineoplastic Agents; Camptothecin; Doxorubicin; Humans; Indoles; Irinotecan; Limit of Detection; Paclitaxel; Pyrroles; Spectrum Analysis, Raman; Sunitinib; Surface Properties | 2016 |
VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Elongin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Mutation, Missense; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Sunitinib; Transfection; Tumor Suppressor Protein p53; Von Hippel-Lindau Tumor Suppressor Protein | 2017 |
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib | 2017 |
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Irinotecan; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; Thyroid Carcinoma, Anaplastic | 2017 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2017 |
A theranostic nanocomposite system based on iron oxide-drug nanocages for targeted magnetic field responsive chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Drug Delivery Systems; Ferric Compounds; HeLa Cells; Humans; Magnetic Fields; MCF-7 Cells; Nanocomposites; Neoplasms; Pyrroles; Quinones; Theranostic Nanomedicine | 2018 |
NIR-controlled morphology transformation and pulsatile drug delivery based on multifunctional phototheranostic nanoparticles for photoacoustic imaging-guided photothermal-chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Drug Liberation; Fluorescent Dyes; Heterografts; Humans; Hypothermia, Induced; Infrared Rays; Lasers; Mice; Nanocapsules; Neoplasms; Photoacoustic Techniques; Photochemotherapy; Polyhydroxyethyl Methacrylate; Polymers; Prodrugs; Pyrroles; Theranostic Nanomedicine | 2018 |
Covalent binders in drug discovery.
Topics: Aminoglycosides; Benzodiazepines; Camptothecin; Drug Discovery; Indoles; Molecular Dynamics Simulation; Protein Binding; Proteins; Pyrans; Pyrroles | 2019 |
Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Female; Fluorescence; Hyaluronic Acid; Hyperthermia, Induced; Immunity; Immunotherapy; Mammary Neoplasms, Animal; Mice; Nanoparticles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Optical Imaging; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles; Tissue Distribution | 2019 |
D-Ring-Modified Analogues of Luotonin A with Reduced Planarity: Design, Synthesis, and Evaluation of Their Topoisomerase Inhibition-Associated Cytotoxicity.
Topics: Alkaloids; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Poly-ADP-Ribose Binding Proteins; Pyrroles; Quinones; Solubility; Structure-Activity Relationship; Topoisomerase Inhibitors | 2019 |